Ontology highlight
ABSTRACT: Importance
In the IMspire150 trial, triplet treatment with atezolizumab and vemurafenib plus cobimetinib significantly improved progression-free survival (PFS) compared with vemurafenib plus cobimetinib alone for treatment of BRAF V600 variation metastatic melanoma. However, considering high cost of this combination, it is unclear if the incremental cost is worth the additional survival benefit.Objective
To evaluate the cost-effectiveness of atezolizumab and vemurafenib plus cobimetinib vs vemurafenib plus cobimetinib alone in patients with newly diagnosed unresectable BRAF V600 variation metastatic melanoma from the US health care perspective.Design, setting, and participants
This economic evaluation study used a 3-state partitioned survival model to assess the cos
SUBMITTER: Cai C
PROVIDER: S-EPMC8586909 | biostudies-literature | 2021 Nov
REPOSITORIES: biostudies-literature